Could XAI harm patients in time-sensitive environments?

By Andreas Wabro. Achieving transparency and interpretability of algorithmic predictions remains an important research goal for many AI experts around the world. In particular, the epistemic benefits of explainable AI (XAI) methods have been widely discussed, and especially in the context of healthcare, international institutions and academic experts often call for measures to improve physicians’ […]

Read More…

Medical research with human samples and health data—why ‘dynamic’ consent is not the solution

By Andreas Bruns and Eva C Winkler. Informed consent is a central principle of medical research ethics. Traditionally, consent is required to respect the autonomy of human research subjects—their right to make their own, informed decision about whether or not to participate in medical research. However, this principle has come under significant pressure with the […]

Read More…

If Marc is Suzanne’s father, does it follow that Suzanne is his child?

By Daniela Cutas, Anna Smajdor, Kristien Hens, and Emma Moormann According to the respondents in our study, the short answer is: not necessarily. We drafted a series of vignettes in which we explored the relationships between reproduction, genes, and parenthood. We wanted to understand the impact that the degree of genetic relatedness might have on […]

Read More…

Expanding the mind and rights of patients with implantable BCIs

By Guido Cassinadri and Marcello Ienca Implantable brain-computer interfaces (iBCI) are implantable systems that record quantitative neural data and use them to deliver various responses such as therapeutic, diagnostic, or preventive interventions. BCIs have been used inter alia to predict seizures in epileptic patients by monitoring their neural data and either delivering electrical stimulation or […]

Read More…

Mind the anticipatory gap: factoring future moral change into the governance of human genome editing

By John Danaher. Human genome editing is a potentially transformative emerging technology. Current clinical trials of CRISPR, for example, suggest it can be used as a therapeutic to treat a wide range of hereditary and acquired diseases. More speculatively, it could also be used as an enhancer, improving the capacities of generally normal or healthy […]

Read More…

Making visible the invisible elements of clinical ethics consultation

By Clare Delany, Sharon Feldman, Barbara Kameniar, and Lynn Gillam. In our article, ‘Making clinical ethics facilitation visible and accessible: Seven steps of the Critical Dialogue method of Ethics Consultation’, we detail our method of clinical ethics facilitation, broken down into seven steps. We also share the rationale for the various steps, and provide concrete […]

Read More…